Cartesian Therapeutics (RNAC) Operating Leases: 2018-2025
Historic Operating Leases for Cartesian Therapeutics (RNAC) over the last 7 years, with Sep 2025 value amounting to $12.6 million.
- Cartesian Therapeutics' Operating Leases fell 13.98% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year decrease of 13.98%. This contributed to the annual value of $11.1 million for FY2024, which is 26.67% up from last year.
- Latest data reveals that Cartesian Therapeutics reported Operating Leases of $12.6 million as of Q3 2025, which was down 5.59% from $13.3 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Operating Leases registered a high of $14.9 million during Q2 2024, and its lowest value of $8.6 million during Q4 2021.
- In the last 3 years, Cartesian Therapeutics' Operating Leases had a median value of $11.3 million in 2023 and averaged $12.1 million.
- Per our database at Business Quant, Cartesian Therapeutics' Operating Leases fell by 14.00% in 2021 and then skyrocketed by 39.79% in 2024.
- Over the past 5 years, Cartesian Therapeutics' Operating Leases (Quarterly) stood at $8.6 million in 2021, then increased by 16.95% to $10.1 million in 2022, then decreased by 12.59% to $8.8 million in 2023, then climbed by 26.67% to $11.1 million in 2024, then dropped by 13.98% to $12.6 million in 2025.
- Its Operating Leases stands at $12.6 million for Q3 2025, versus $13.3 million for Q2 2025 and $14.1 million for Q1 2025.